HC Wainwright Boosts Earnings Estimates for Tyra Biosciences

Tyra Biosciences, Inc. (NASDAQ:TYRA) – Research analysts at HC Wainwright upped their Q2 2026 earnings per share estimates for Tyra Biosciences in a research note issued on Tuesday, March 3rd. HC Wainwright analyst M. Kapoor now anticipates that the company will earn ($0.65) per share for the quarter, up from their prior estimate of ($0.66). HC Wainwright currently has a “Buy” rating and a $45.00 target price on the stock. The consensus estimate for Tyra Biosciences’ current full-year earnings is ($1.57) per share. HC Wainwright also issued estimates for Tyra Biosciences’ Q3 2026 earnings at ($0.67) EPS, Q4 2026 earnings at ($0.70) EPS and FY2026 earnings at ($2.66) EPS.

Tyra Biosciences (NASDAQ:TYRA) last announced its quarterly earnings results on Monday, March 2nd. The company reported ($0.57) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.54) by ($0.03).

Several other equities research analysts also recently weighed in on TYRA. Piper Sandler raised their price target on shares of Tyra Biosciences from $33.00 to $42.00 and gave the company an “overweight” rating in a research report on Friday, January 23rd. Weiss Ratings reissued a “sell (d-)” rating on shares of Tyra Biosciences in a report on Wednesday, January 21st. William Blair began coverage on Tyra Biosciences in a report on Tuesday, February 10th. They set an “outperform” rating on the stock. Barclays started coverage on shares of Tyra Biosciences in a research note on Tuesday, January 27th. They set an “overweight” rating for the company. Finally, Wall Street Zen downgraded Tyra Biosciences from a “hold” rating to a “sell” rating in a research note on Saturday, January 24th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $42.33.

Tyra Biosciences Stock Performance

Shares of Tyra Biosciences stock opened at $35.27 on Thursday. The company has a 50-day simple moving average of $29.90 and a two-hundred day simple moving average of $20.86. The stock has a market capitalization of $1.90 billion, a PE ratio of -17.55 and a beta of 1.06. Tyra Biosciences has a 52-week low of $6.42 and a 52-week high of $35.96.

Insider Buying and Selling at Tyra Biosciences

In related news, Director Robert J. More sold 10,000 shares of the stock in a transaction dated Friday, December 19th. The stock was sold at an average price of $25.00, for a total transaction of $250,000.00. Following the completion of the sale, the director owned 3,823,425 shares in the company, valued at approximately $95,585,625. This trade represents a 0.26% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 15.20% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Tyra Biosciences

Several hedge funds have recently modified their holdings of the stock. Caitong International Asset Management Co. Ltd purchased a new position in Tyra Biosciences during the fourth quarter valued at $51,000. Chung Wu Investment Group LLC purchased a new position in shares of Tyra Biosciences during the fourth quarter valued at about $53,000. Federated Hermes Inc. increased its holdings in shares of Tyra Biosciences by 586.3% in the third quarter. Federated Hermes Inc. now owns 2,155 shares of the company’s stock worth $30,000 after purchasing an additional 1,841 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its stake in Tyra Biosciences by 25.9% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,594 shares of the company’s stock valued at $68,000 after buying an additional 534 shares during the last quarter. Finally, The Manufacturers Life Insurance Company purchased a new position in Tyra Biosciences during the 4th quarter valued at approximately $220,000. Hedge funds and other institutional investors own 84.14% of the company’s stock.

Tyra Biosciences Company Profile

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.